Evidence map›Paper›PMID 42180039›Full record

ArticleFrontiers in oncology2026

Case Report: Proton beam therapy - friend or foe for patients with

Liv Cathrine Heggebø, Lars Fredrik Fjæra, Frank Leonel Bello Garrote, Ida Maria Henriksen Borgen, Hanne Blakstad, Taran Paulsen Hellebust, Cathrine Saxhaug, Kjetil Knutstad, Hillevi Rylander, Thomas Henry and 4 more

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Liv Cathrine HeggebøDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Lars Fredrik FjæraDepartment of Medical Physics, Oslo University Hospital, Oslo, Norway.
Frank Leonel Bello GarroteDepartment of Medical Physics, Oslo University Hospital, Oslo, Norway.
Ida Maria Henriksen BorgenDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Hanne BlakstadDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Taran Paulsen HellebustDepartment of Medical Physics, Oslo University Hospital, Oslo, Norway.
Cathrine SaxhaugDepartment of Radiology, Oslo University Hospital, Oslo, Norway.
Kjetil KnutstadDepartment of Radiology, Oslo University Hospital, Oslo, Norway.
Hillevi RylanderThe Skandion Clinic, Uppsala, Sweden.
Thomas HenryDepartment of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden.
Magnus GustafssonThe Skandion Clinic, Uppsala, Sweden.
Katja WerleniusDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Malin BlomstrandDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Petter BrandalDepartment of Oncology, Oslo University Hospital, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Proton beam therapy is increasingly implemented for lower-grade gliomas worldwide, aiming to reduce radiation exposure to healthy tissue and lower treatment related toxicity. However, robust clinical evidence of the benefit of radiotherapy delivered with protons compared to photons is lacking. Importantly, although proton therapy offers potential benefits compared to photon radiotherapy, it is still ionizing radiation and can be associated with severe complications. Emerging concerns include a possible increase of radiotherapy-induced contrast-enhancing lesions. Case presentation: A healthy woman in her mid-forties underwent a subtotal resection for an Conclusion: This case highlights that although proton beam therapy is considered safe and potentially encumbered with fewer side effects than photon radiotherapy, serious complications may occur. Careful consideration of timing and execution of adjuvant therapy for lower-grade gliomas is essential. Randomized controlled trials are necessary to disclose if proton beam therapy is beneficial or not in lower-grade gliomas.

Indexed as

case reportIDH-mutated gliomaoligodendrogliomaproton therapyradionecrosisRICE

Identifiers

PMID42180039
PMCPMC13193975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.